Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 5/20 | 0.61 |
| ▸ | CDK1 | P06493 | 1/20 | 0.59 |
| ▸ | CDK2 | P24941 | 1/20 | 0.59 |
| ▸ | CDK8 | P49336 | 1/20 | 0.59 |
| ▸ | SRC | P12931 | 6/20 | 0.57 |
| ▸ | RET | P07949 | 3/20 | 0.56 |
| ▸ | KDR | P35968 | 2/20 | 0.54 |
| ▸ | ABL1 | P00519 | 9/20 | 0.54 |
| ▸ | ABL2 | P42684 | 4/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24449095 | 0.90 | FGFR4 (0.61) | FGFR4CDK1CDK2CDK8SRC | |
| SCHEMBL24449284 | 0.90 | SRC (0.68) | FGFR4CDK1CDK2CDK8SRC | |
| SCHEMBL24449129 | 0.87 | FGFR4 (0.64) | FGFR4CDK1CDK2CDK8SRC | |
| SCHEMBL24448277 | 0.86 | SRC (0.60) | FGFR4CDK1CDK2CDK8SRC | |
| SCHEMBL24449287 | 0.86 | ABL1 (0.59) | FGFR4CDK1CDK2CDK8SRC | |
| SCHEMBL24449288 | 0.85 | FGFR4 (0.57) | FGFR4CDK1CDK2CDK8SRC | |
| SCHEMBL24449233 | 0.85 | FGFR4 (0.60) | FGFR4CDK1CDK2CDK8SRC | |
| SCHEMBL24449140 | 0.80 | ABL1 (0.50) | FGFR4CDK1CDK2CDK8SRC | |
| SCHEMBL24449100 | 0.79 | CDK1 (0.54) | FGFR4CDK1CDK2CDK8SRC | |
| SCHEMBL24449085 | 0.79 | ABL1 (0.62) | FGFR4CDK1CDK2CDK8SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | CORNELL UNIVERSITY | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | PTGES, PTGS1, PTGES2 | FGFR4 4833/4885CDK1 3629/4885CDK2 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.